Get the Stockscreener App
7.61
2.99%
-0.07
Passage Bio Inc stock is traded at $7.61, with a volume of 57,988.
It is down -2.99% in the last 24 hours and down -6.29% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$7.68
Open:
$7.71
24h Volume:
57,988
Relative Volume:
1.75
Market Cap:
$23.68M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-6.5043
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
+3.47%
1M Performance:
-6.29%
6M Performance:
+1,786%
1Y Performance:
+1,084%
1-Day Range:
$7.41
$7.91
1-Week Range:
$7.00
$7.91
52-Week Range:
$0.257
$9.00
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
7.45 | 24.41M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.76 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.33 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.40 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.30 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.16 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Market reaction to Passage Bio Inc.’s recent newsTrade Risk Assessment & Reliable Price Action Trade Plans - newser.com
Will Passage Bio Inc. price bounce be sustainable2025 AllTime Highs & Verified Momentum Stock Alerts - newser.com
Why Passage Bio Inc. stock remains a top recommendationWeekly Profit Report & Fast Exit and Entry Strategy Plans - newser.com
How to recover losses in Passage Bio Inc. stockMarket Trend Report & Growth Oriented Trading Recommendations - newser.com
Why Passage Bio Inc. is moving todayJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com
Using economic indicators to assess Passage Bio Inc. potentialWeekly Profit Report & Free Daily Entry Point Trade Alerts - newser.com
Combining machine learning predictions for Passage Bio Inc.Portfolio Risk Summary & Verified Entry Point Signals - newser.com
Can Passage Bio Inc. stock attract ESG capital inflowsEarnings Overview Report & Real-Time Buy Zone Alerts - newser.com
Passage Bio Inc. stock trendline breakdown2025 Volatility Report & Safe Capital Growth Plans - newser.com
Is Passage Bio Inc. stock bottoming outJuly 2025 Snapshot & Advanced Swing Trade Entry Plans - newser.com
Applying chart zones and confluence areas to Passage Bio Inc.2025 Biggest Moves & Weekly Watchlist for Hot Stocks - newser.com
Multi asset correlation models including Passage Bio Inc.2025 Institutional Moves & Long Hold Capital Preservation Plans - newser.com
How Passage Bio Inc. stock reacts to global recession fearsJuly 2025 Big Picture & Low Drawdown Trading Techniques - newser.com
What momentum shifts mean for Passage Bio Inc.2025 Dividend Review & Free Real-Time Market Sentiment Alerts - newser.com
Smart tools for monitoring Passage Bio Inc.’s price action2025 Momentum Check & Real-Time Chart Pattern Alerts - newser.com
Why Passage Bio Inc. stock could rally in 2025July 2025 Recap & Growth Focused Stock Reports - newser.com
Ocugen to Announce Third-Quarter 2025 Results and Business Update on November 5 - MyChesCo
Predicting Passage Bio Inc. trend using moving averagesJuly 2025 Analyst Calls & Short-Term High Return Ideas - newser.com
Can you recover from losses in Passage Bio Inc.2025 Market Overview & Precise Buy Zone Tips - newser.com
Ranking Passage Bio Inc. among high performing stocks via toolsWeekly Profit Report & Verified Swing Trading Watchlist - newser.com
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):